![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, August 10, 2017 10:32:36 AM
Now to see PS Targeting included.... on top of the fact that Troy Luster was on the PS Targeting patents with Dr Phil Thorpe and Peregrine CEO Steve King, it makes me curious to what extent would Troy Luster play in this? Troy Luster went to Dana Farber and always wondered why and just another puzzle piece seeing Dana Farber come to realize PS Targeting was required
Link below pg 16/17 showing undisclosed drug with Evotec (worked with Troy Luster / Dana Farber
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=106231165
_______
Sanofi and Novartis snap up immuno-oncology candidates
Separate licensing deals see the firms look to catch up with the category's leaders
11th January 2016
Sanofi and Novartis have added to their early-stage cancer immunotherapy pipelines with new licensing deals as they try to catch up with the leaders in the category.
Details of the Novartis agreement are sketchy, but the company says it has licensed four preclinical programmes from Massachusetts-based Surface Oncology's portfolio which target "regulatory T cell populations, inhibitory cytokines, and immunosuppressive metabolites in the tumour microenvironment".
The candidates will be developed as monotherapies as well as in combination with Novartis' own pipeline of immuno-oncology candidates, which includes seven clinical programmes with five more scheduled to start trials this year.
Novartis' immuno-oncology aspirations gathered pace at the start of 2015 when it set up a dedicated R&D team led by cancer vaccine pioneer Glenn Dranoff, and the portfolio is currently led by chimeric antigen receptor T-cell (CART) candidate CTL109 which is in phase II trials for chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and multiple myeloma.
Meanwhile, after some disappointments with in-house R&D, Sanofi's activities in immuno-oncology were kick-started by a $1.8bn alliance with Regeneron and a $1.5bn deal with BioNtech - signed last year alongside smaller deals with Selecta, Evotec and Apeiron Biologics.
..
..
http://www.pmlive.com/pharma_news/sanofi_and_novartis_snap_up_immuno-oncology_candidates_903270?SQ_DESIGN_NAME=2&
________ some tidbits of info below but digging deeper into Evotec ...etc
Under the terms of this research tool licence, Evotec gains access to IP related to CRISPR-Cas9 and will apply the technology to its drug discovery offerings and R&D activities, especially for the development of research tools and in target identification, and to further strengthen its post phenotypical screening target deconvolution platform.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=123807225
Recent CDMO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 11:50:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 11:48:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/15/2024 08:40:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/12/2024 08:30:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:02:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:02:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:01:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:01:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:00:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:00:45 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/11/2024 12:23:26 AM
- Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024 • GlobeNewswire Inc. • 07/02/2024 08:05:04 PM
- Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024 • GlobeNewswire Inc. • 07/01/2024 11:00:21 AM
- Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance • GlobeNewswire Inc. • 05/23/2024 12:05:46 PM
- Avid Bioservices to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 05/07/2024 08:05:11 PM
- Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 04/24/2024 09:25:33 PM
- Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q • GlobeNewswire Inc. • 03/20/2024 11:00:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:30:11 AM
- Avid Bioservices Announces Pricing of Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/07/2024 04:58:48 AM
- Avid Bioservices Announces Proposed Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/06/2024 09:32:07 PM
- Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 03/06/2024 09:31:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:30:18 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:57:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2024 12:34:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:39:18 AM
Kona Gold Beverages, Inc. Announces Strategic Initiatives and Corporate Direction Changes • KGKG • Aug 2, 2024 2:00 PM
POET and Luxshare Tech Expand Product Offerings for Artificial Intelligence Networks • POET • Aug 1, 2024 9:28 AM
Management Discusses Financial Filings of Global Arena Holding Inc., for 10-K 2023 and 10-Q, 1st Quarter 2024 • GAHC • Aug 1, 2024 9:14 AM
VAYK Announces LOI to Acquire $1 Million Home Service Company to Support Airbnb Business • VAYK • Aug 1, 2024 9:00 AM
Duane Forrester Joins INDEXR as SVP of Search • MONI • Jul 31, 2024 11:46 AM
Lingerie Fighting Championships Help Fulfill Death-Bed Promise With First Major Motion Picture • BOTY • Jul 31, 2024 9:00 AM